newsfilter
← Latest News
GlobeNewswire·

Allena Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Corporate Progress

ALLN-346, a first-in-class, non-absorbed, orally administered enzyme in development for the treatment of hyperuricemia and gout in the setting of advanced chronic kidney disease, receives Fast Track Designation from FDA Two Phase 2a trials for ALLN-34